Sandra Torres-Ruiz
Overview
Explore the profile of Sandra Torres-Ruiz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torres-Ruiz S, Garrido-Cano I, Lameirinhas A, Burgues O, Hernando C, Martinez M, et al.
Cell Death Discov
. 2024 Aug;
10(1):372.
PMID: 39174500
Despite progress in breast cancer treatment, a significant portion of patients still relapse because of drug resistance. The involvement of microRNAs in cancer progression and chemotherapy response is well established....
2.
Garcia A, Torres-Ruiz S, Vila L, Villarroel-Vicente C, Bernabeu A, Eroles P, et al.
RSC Med Chem
. 2023 Nov;
14(11):2327-2341.
PMID: 38020071
Synthesis of three series of 2-aminopropyl derivatives containing a benzopyran nucleus was performed to evaluate their performance against triple-negative breast cancer cell lines (MDA-MB-231 and MDA-MB-436) and normal breast epithelial...
3.
Tapia M, Hernando C, Martinez M, Burgues O, Tebar-Sanchez C, Lameirinhas A, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760491
HER2-positive breast cancer accounts for 15-20% of all breast cancer cases. This subtype is characterized by an aggressive behavior and poor prognosis. Anti-HER2 therapies have considerably improved the natural course...
4.
Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046799
Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of...
5.
Torres-Ruiz S, Tormo E, Garrido-Cano I, Lameirinhas A, Rojo F, Madoz-Gurpide J, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835014
Due to the lack of specific targets, cytotoxic chemotherapy still represents the common standard treatment for triple-negative breast patients. Despite the harmful effect of chemotherapy on tumor cells, there is...
6.
Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgues O, Rovira A, Martinez M, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362083
Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens...
7.
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, et al.
Cancer Metastasis Rev
. 2021 Sep;
41(1):77-105.
PMID: 34524579
Breast cancer is the most frequent cancer in women worldwide. Despite the improvement in diagnosis and treatments, the rates of cancer relapse and resistance to therapies remain higher than desirable....